Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women

NCT03271489 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT03271489
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03271489 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women
Lead sponsor
AbbVie
Phase
Phase 3
Overall status
Completed
Start date
September 13, 2017
Completion date
June 28, 2024
Enrollment
478 (actual)
Sites
157

Conditions

As the registry lists them; a condition with its own page is linked.

heavy menstrual bleeding, uterine fibroids